Antidepressant-Induced Activation in Children and Adolescents: Risk, Recognition and Management
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The tolerability of antidepressants is poorly characterized in children and adolescents with depressive and anxiety disorders. Among adverse events that affect the tolerability of antidepressants in youth is activation, a cluster of symptoms that represent a hyperarousal event characterized by impulsivity, restlessness, and/or insomnia. This cluster of symptoms was first identified as a side effect of selective serotonin and selective serotonin norepinephrine inhibitors (SSRIs and SSNRIs) in the early 1990s; however, activation remains poorly characterized in terms of prevalence, risk factors, and pathophysiology. This paper describes the pathophysiology of antidepressant-related activation, predictors of activation and clinical management in youth with depressive and anxiety disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 2×
“and includes items from other rating scales that measure these symptoms: suicidality—Columbia Suicide Severity Rating Scale(15); akathisia—Barnes Akathisia Scale and mania—Young Mania Rating Scale.(16) At present, the TEASAP has been utilized to track activation-related adverse events in antidepressant-treated pediatr…”
MethodPosner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety
Walkup, J. T., Albano, A. M., Piacentini, J., Birmaher, B., Compton, S. N., Sherrill, J. T., Ginsburg, G. S., Rynn, M. A., McCracken, J., Waslick, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804633 · Cited by 1,442
Bridge, J. A., Iyengar, S., Salary, C. B., Barbe, R. P., Birmaher, B., Pincus, H. A., Ren, L., & Brent, D. A. (2007) · JAMA · doi:10.1001/jama.297.15.1683 · Cited by 1,086
Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Hammad, T. A., Laughren, T., & Racoosin, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.332 · Cited by 1,054
Cipriani, A., Zhou, X., Del Giovane, C., Hetrick, S. E., Qin, B., Whittington, C., Coghill, D., Zhang, Y., Hazell, P., Leucht, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30385-3 · Cited by 734
Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents
Walkup, J. T., Labellarte, M. J., Riddle, M. A., Pine, D. S., Greenhill, L., Klein, R., Davies, M., Sweeney, M., Abikoff, H., Hack, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104263441703 · Cited by 588
The Perinatal Depression Treatment Cascade: Baby Steps Toward Improving Outcomes
Cox, E. Q., Sowa, N. A., Meltzer-Brody, S. E., & Gaynes, B. N. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15r10174 · Cited by 426
Guidelines for Adolescent Depression in Primary Care (GLAD-PC): II. Treatment and ongoing management
Cheung, A. H., Zuckerbrot, R. A., Jensen, P. S., Ghalib, K., Laraque, D., Stein, R. E. K., & and the GLAD-PC Steering Group (2007) · Pediatrics · doi:10.1542/peds.2006-1395 · Cited by 336
Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients.
Godlewska, B. R., Norbury, R., Selvaraj, S., Cowen, P. J., & Harmer, C. J. (2012) · Psychological Medicine · doi:10.1017/s0033291712000591 · Cited by 244
Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214 · cited 3×
“The short allele may be associated with an increased risk of depressive and anxiety disorders and may—in some samples—be associated with decreased response to SSRIs.44,45 However, given that these polymorphisms relate to the “site of action” for antidepressants, there has been some investigation of their role in SSRI/…”
BackgroundStrawn, J. R., Welge, J. A., Wehry, A. M., Keeshin, B., & Rynn, M. A. (2015) · Depression and Anxiety · doi:10.1002/da.22329 · Cited by 183 · cited 2×
“Despite the recognition of antidepressant-related activation as a risk factor for medication discontinuation and suicidality, the activation syndrome lacks a clear definition.(2,13) Currently, several symptoms are considered to be activation-related adverse events: disinhibition, impulsivity, insomnia, restlessness, h…”
BackgroundSelf-citationA Randomized Controlled Trial of Venlafaxine ER Versus Placebo in Pediatric Social Anxiety Disorder
March, J. S., Entusah, A. R., Rynn, M., Albano, A. M., & Tourian, K. A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.02.025 · Cited by 156
Maslowsky, J., Mogg, K., Bradley, B. P., McClure-Tone, E., Ernst, M., Pine, D. S., & Monk, C. S. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0049 · Cited by 125
Walkup, J. T. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16091059 · Cited by 112
Offidani, E., Fava, G. A., Tomba, E., & Baldessarini, R. J. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000345316 · Cited by 94 · cited 1×
“Specifically, a recent meta-analysis failed to find significant differences in the relative risk of “excessive mood elevation” observed in studies (κ 1⁄4 42) of patients with anxiety (κ 1⁄4 17) or depressive disorders (κ 1⁄4 25).(38) In this meta-analysis, the “mood elevation” symptoms included insomnia, restlessness,…”
BackgroundAntidepressants and Psychostimulants in Pediatric Populations: Is there an Association with Mania?
Goldsmith, M., Singh, M., & Chang, K. (2011) · Pediatric Drugs · doi:10.2165/11591660-000000000-00000 · Cited by 79
Strawn, J. R., Adler, C. M., McNamara, R. K., Welge, J. A., Bitter, S. M., Mills, N. P., Barzman, D. H., Cerullo, M. A., Chang, K. D., Strakowski, S. M., et al. (2014) · Bipolar Disorders · doi:10.1111/bdi.12113 · Cited by 70
Self-citation
Cited by
Walter, H. J., Bukstein, O. G., Abright, A. R., Keable, H., Ramtekkar, U., Ripperger-Suhler, J., & Rockhill, C. (2020) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2020.05.005 · Cited by 335
Solmi, M., Fornaro, M., Ostinelli, E. G., Zangani, C., Croatto, G., Monaco, F., Krinitski, D., Fusar‐Poli, P., & Correll, C. U. (2020) · World Psychiatry · doi:10.1002/wps.20765 · Cited by 324
Walter, H. J., Abright, A. R., Bukstein, O. G., Diamond, J., Keable, H., Ripperger-Suhler, J., & Rockhill, C. (2023) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2022.10.001 · Cited by 193
Serafini, G., Parisi, V. M., Aguglia, A., Amerio, A., Sampogna, G., Fiorillo, A., Pompili, M., & Amore, M. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17072393 · Cited by 172
Murphy, S. E., Capitão, L. P., Giles, S. L. C., Cowen, P. J., Stringaris, A., & Harmer, C. J. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00154-1 · Cited by 112
Metadata
- Authors
- Luft, M. J., Lamy, M., DelBello, M. P., McNamara, R. K., & Strawn, J. R.
- Venue
- Current Problems in Pediatric and Adolescent Health Care
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 48
- Issue
- 2
- Pages
- 50-62
- ISSN
- 1538-3199 (ISSN-L)
- 1538-5442
- OpenAlex
- W2786140189
- Cited by
- 106
- References
- 19
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.